Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)
Clinical trial NCT07016230 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT07016230
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-02
- Primary completion
- 2026-10-18
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.